보험 및 인슈어테크 리포트 (2026-11-01)
Domestically, discussions to enact the Digital Healthcare Act have restarted, and the Korea Health Industry Development Institute held a digital healthcare bootcamp to help build the industry ecosystem. Yuhan Corporation and Boehringer Ingelheim expanded their partnership beyond co-selling drugs into digital healthcare. Overseas, rising ACA premiums and insurer withdrawals are heightening uncertainty in the global healthcare insurance market.
Insurance Industry and Insurtech Report — 2026-11-01
Domestic Insurance Industry Trends
The domestic insurance and healthcare sectors are actively moving toward digital transformation and regulatory response.
-
Resumption of Discussions on the Digital Healthcare Act: To tackle the AI era, debates for and against the enactment of the 'Digital Healthcare Act'—which focuses on nurturing the digital healthcare industry and utilizing health and medical information—are flaring up again.
Digital Healthcare Act discussion article image -
KHIDI Hosts Digital Healthcare Bootcamp (DHB 2026): The Korea Health Industry Development Institute (KHIDI) will host the '1st Digital Healthcare Bootcamp' on the 3rd and 4th of next month at Westin Seoul Parnas in Gangnam-gu, Seoul. This event will provide expert consulting on FDA approvals in the US, compliance with European AI regulations, and attracting investment to help domestic digital healthcare companies expand overseas.
Announcement for the 1st Digital Healthcare Bootcamp -
Yuhan Corporation and Boehringer Ingelheim Korea Push Digital Healthcare Cooperation: Yuhan Corporation and Boehringer Ingelheim Korea are expanding their 16-year pharmaceutical co-sales partnership into digital healthcare, patient support, and medical-scientific exchanges. The two companies plan to combine their global R&D capabilities with domestic business experience to expand patient treatment opportunities.
Image related to digital healthcare cooperation between Yuhan Corporation and Boehringer Ingelheim Korea -
Pharmaceutical Companies Expand into Digital Healthcare: Domestic pharmaceutical companies are expanding the application scope of digital healthcare beyond chronic disease management like electrocardiograms and blood pressure to gait analysis, sleep, and obesity management. This is interpreted as a strategy to counter deteriorating pharmaceutical profitability.
Image related to the expansion of pharmaceutical digital healthcare businesses
Global Insurtech and Healthcare Achievements
In overseas insurance and healthcare markets, attention is drawn to premium hikes and insurer market withdrawals driven by policy changes.
-
US ACA Premiums to Rise by 13%: Premiums for Affordable Care Act (ACA) enrollees in the US are set to increase by an average of 13% for 2027. This measure comes on top of previous steep hikes alongside the weakening of the program under the Trump administration.
NYT article image related to ACA premium hikes -
Tracking ACA Market Insurer Participation Changes: KFF is tracking insurer exits and new entries in the ACA marketplaces for 2027. Changes in insurer participation directly impact consumer choices and market competitiveness.
ACA Marketplace insurer participation change tracking dashboard -
Health In Tech to Release Q3 Earnings: Health In Tech, Inc., an AI-based insurtech platform company, is scheduled to announce its Q3 2026 financial results on November 12.
Market Insights and Analysis
Based on the collected cases, the convergence trend of insurance and healthcare can be analyzed as follows:
- Balance Between Regulation and Industry Ecosystem Building: Domestically, pros and cons debates regarding the enactment of the 'Digital Healthcare Act' are ongoing, while a bootcamp supporting companies' overseas expansion is being held centered around KHIDI. This indicates that establishing a regulatory framework and supporting industry nurturing are happening simultaneously.
- Blurring Boundaries Among Pharmaceuticals, Insurance, and Healthcare: Like the cooperation case between Yuhan Corporation and Boehringer Ingelheim, traditional pharmaceutical co-sales relationships are expanding into digital healthcare and patient support. This is expected to lead to the development of data-driven customized insurance and healthcare products, aligned with insurers (the fourth player) entering the healthcare ecosystem.
- Global Policy Risks and Premium Volatility: The surge in US ACA market premiums (13%) and fluctuations in insurer participation show that the global healthcare insurance market is extremely sensitive to policy uncertainty.
Quiet week for X: While new product launches or large-scale M&A news by major domestic insurers have been limited over the past 24 hours, notable ecosystem changes such as regulatory debates and pharmaceutical healthcare expansions stood out.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
